Objective Despite the increase in incidence of non-melanoma skin cancers (NMSC), deaths are relatively rare. The goal of treatment is to prevent the recurrence of the disease and to increase the quality of life (QoL). The QoL and the cost of treatment are becoming more important treatment goals, as nowadays NMSC are rarely life-threatening. This study aims to assess and compare the QoL in patients with NMSC, psoriasis, and vitiligo using three validated QoL instruments. Methods A total of 150 patients were included in this study, with 50 patients each diagnosed with NMSC, psoriasis, and vitiligo. The QoL was assessed using the European Organization for Research and Treatment of Cancer Core QoL Questionnaire (EORTC QLQ-C30), the Dermatology Life Quality Index (DLQI), and the World Health Organization Quality of Life Scale Short Form (WHOQOL-BREF). Sociodemographic data and disease severity were also recorded. Results The study found that NMSC and psoriasis patients had similar QoL scores, with both groups showing more significant impairment in QoL than vitiligo patients. Psoriasis patients experienced greater deterioration in daily activities and personal relationships, while QoL in work, school, and treatment domains was worse in both NMSC and psoriasis patients compared to vitiligo patients. A negative correlation was observed between disease duration and the physical health domain subscale of the WHOQOL-BREF, as well as the work and school subscale of the DLQI, in vitiligo patients; and between disease duration and the work and school subscale of the DLQI in NMSC patients. Conclusion The findings underscore the significant impact of NMSC on patients’ QoL, highlighting the importance of comprehensive management strategies in these conditions. The similarity in QoL scores obtained across all groups using DLQI and WHOQOL-BREF suggests that the WHOQOL-BREF, a general health QoL scale, can be effectively used alongside the DLQI, a dermatology-specific QoL scale, to assess QoL in dermatologic diseases.
9 April 2026 in Diagnostic Microbiology and Infectious Disease
Introduction: Prurigo pigmentosa (PP) is a rare inflammatory skin disease, first described in 1971 in Japan. The condition is characterized by the abrupt appearance of pruritic, erythematous, maculopapular lesions that typically resolve within several days to weeks, resulting in reticulated hyperpigmentation. Objective: This study aimed to retrospectively evaluate six cases of prurigo pigmentosa in light of clinical and histopathological features and treatment responses. Methods: This retrospective study was performed at the Department of Dermatology, Bursa Uludag University Faculty of Medicine, Bursa, Türkiye, from 2022 to 2025. Six patients were included in the study, and their demographic characteristics, presenting complaints, clinical and histopathological findings, laboratory results, and treatment responses were assessed. Results: Six patients with prurigo pigmentosa were evaluated. All presented with symmetrical, pruritic erythematous eruptions on the trunk and back. Three had a history of ketogenic diet or rapid weight loss. Five patients received oral doxycycline (100–200 mg/day) and demonstrated marked clinical improvement. One patient initially treated with corticosteroids showed worsening and was switched to doxycycline. Histopathology revealed spongiotic dermatitis (N=3), eosinophilic infiltration (N=2), and interface dermatitis (N=1). Elevated serum IgE levels were detected in two cases. Conclusion: In conclusion, prurigo pigmentosa should be suspected in young patients with symmetric pruritic eruptions and a history of ketosis. Awareness of its variable histopathological findings and its strong association with dietary or metabolic triggers is essential to timely diagnosis. The rapid and consistent response to tetracycline-class antibiotics, particularly doxycycline, underscores their value as both a diagnostic aid and a preferred therapeutic option.
28 November 2025 in Journal of Cosmetic Dermatology